Guggenheim Capital’s $1.2 Billion Healthcare Stock Portfolio: JNJ, MD, GILD, AMGN

Wall St. Watchdog reveals information regarding Guggenheim Capital LLC’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 245 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $1.241 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Guggenheim Capital LLC reported holding 831,888 shares with a market value of $55,337,187. This comprised 0.25% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 960,031 shares with a market value of $61,144,373. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is 128,143. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Mednax Inc. (NYSE:MD): On 06/30/2011, Guggenheim Capital LLC reported holding 891,913 shares with a market value of $64,387,202. This comprised 0.29% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 868,551 shares with a market value of $54,406,034. This comprised 0.31% of the total portfolio. The net change in shares for this position over the two quarters is -23,362. About Company: MEDNAX, Inc., through a subsidiary, provides physician management services to hospital-based neonatal, maternal – fetal, pediatric cardiology, and pediatric intensive care specialties. The Company also manages anesthesia practices.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, Guggenheim Capital LLC reported holding 1,163,217 shares with a market value of $48,168,816. This comprised 0.22% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 1,203,683 shares with a market value of $46,702,899. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is 40,466. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Guggenheim Capital LLC reported holding 940,021 shares with a market value of $54,850,224. This comprised 0.25% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 727,583 shares with a market value of $39,987,961. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is -212,438. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Forest Laboratories Inc. (NYSE:FRX): On 06/30/2011, Guggenheim Capital LLC reported holding 1,298,463 shares with a market value of $51,081,535. This comprised 0.23% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 1,265,679 shares with a market value of $38,970,258. This comprised 0.22% of the total portfolio. The net change in shares for this position over the two quarters is -32,784. About Company: Forest Laboratories, Inc. develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses. Forest’s products are marketed in the United States and eastern Europe.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Guggenheim Capital LLC reported holding 2,128,827 shares with a market value of $43,853,837. This comprised 0.2% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 2,103,321 shares with a market value of $37,186,716. This comprised 0.21% of the total portfolio. The net change in shares for this position over the two quarters is -25,506. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Guggenheim Capital LLC reported holding 778,943 shares with a market value of $40,987,980. This comprised 0.19% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 726,713 shares with a market value of $37,164,102. This comprised 0.21% of the total portfolio. The net change in shares for this position over the two quarters is -52,230. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Guggenheim Capital LLC reported holding 1,021,878 shares with a market value of $36,062,076. This comprised 0.16% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 1,019,735 shares with a market value of $33,345,335. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -2,143. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, Guggenheim Capital LLC reported holding 690,418 shares with a market value of $41,646,014. This comprised 0.19% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 531,614 shares with a market value of $32,912,223. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -158,804. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Covidien Plc (NYSE:COV): On 06/30/2011, Guggenheim Capital LLC reported holding 862,147 shares with a market value of $45,892,084. This comprised 0.21% of the total portfolio. On 09/30/2011, Guggenheim Capital LLC reported holding 736,382 shares with a market value of $32,474,445. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -125,765. About Company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.

(Note: Data regarding Guggenheim Capital LLC’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet